Medicine information TUYORY 162mg solution for injection in pre-filled pen

Product code:
W71916001
Quantity:
4
Indicated for:
autoimmune inflammatory diseases
Route of administration:
injectable
Substance:
tocilizumab (monoclonal antibody)
ATC
L04AC07 — Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Interleukin inhibitors
Tocilizumab is a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, used in the treatment of autoimmune inflammatory diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and cytokine release syndrome. By blocking the IL-6 receptor, tocilizumab reduces inflammation and abnormal immune responses.

Tocilizumab is administered either intravenously or subcutaneously, depending on the specific indication and patient preference. The dose and frequency of administration are adjusted based on body weight and disease severity.

Common side effects include upper respiratory tract infections, high blood pressure, headache, and elevated liver enzyme levels. In rare cases, severe adverse reactions such as serious infections or gastrointestinal perforations may occur. Regular monitoring of clinical parameters is essential during treatment.

Tocilizumab is an important therapeutic option for patients with chronic inflammatory diseases, contributing to symptom relief and improved quality of life.

General data about TUYORY 162mg

Substance:
tocilizumab
Date of latest medicines list:
01-06-2026
Product code:
W71916001
Strength:
162mg
Pharmaceutical form:
solution for injection in pre-filled pen
Quantity:
4
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
GEDEON RICHTER PLC. - UNGARIA
Holder:
GEDEON RICHTER PLC. - UNGARIA
Number:
2022/2026/09
Shelf life:
24 months-flaconul unopened

Strengths available for tocilizumab

  • 162mg
  • 200mg
  • 20mg/ml
  • 400mg
  • 80mg

Official documents

The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.

The correspondence between the document and the displayed text is unconfirmed.

Source institution
EMA
Document language
English
Source record: first published
19/05/2026
Source record: last updated
21/08/2026

Warnings:

Anaphylaxis

Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.

Additional monitoring

This medicine is subject to additional monitoring.

Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning

Use during pregnancy only on medical advice.